Advocacy Update: NMDP/Be The Match Hosts a Capitol Hill Briefing
On March 21st in Washington, D.C.,
the National Marrow Donor Program® (NMDP)/Be The Match® held an awareness
briefing celebrating the successful transplant pairing and first-time meeting
of donor, Kyndess Eaggleston and recipient, Kate Jauch.
Read more about Kyndess and Kate's journey >
Economic Report: ICER CAR T-Cell Effectiveness and Value
On March 23, the
Institute for Clinical and Economic Review (ICER) released its Final Evidence
Report of Effectiveness and Value for Chimeric Antigen Receptor (CAR) T-Cell
Therapy for B-Cell Cancers, including childhood B-cell acute lymphoblastic
leukemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma (NHL) in adults.
ICER sought to investigate whether the new CAR T-cell therapies provided a net
clinical benefit and long-term cost-effectiveness when compared to standard
chemoimmunotherapy regimens for specified indications. A key finding on access
to CAR T-cell therapies is that, at current cost ($373,000 per patient) and
during any given year, our health care system can only afford to treat about
one-third of patients eligible to receive axicabtagene ciloleucel (Yescarta)
for relapsed/refractory NHL; this percentage could reach one hundred if the
cost of the drug were discounted to approximately $220,000 per patient. As a
result, a policy recommendation from the policy roundtable discussion was to
implement innovative payment models such as value-based pricing with the
context of affordability, outcomes-based pricing arrangements, consideration of
public contributions to cost of research and development, removal of barriers
to indication-specific pricing, and hospital mark-up practices that reflect
cost-of-care rather than percentage of drug cost.
Read a summary of ICER's report.
Read ICER's full report.
Live Webinar: Coverage and Optimal Reporting of HCT for 2018
On Thursday, April 19, from 11 a.m. to 12:30 p.m. CDT, our experts will review correct coding of
allogeneic stem cell transplants and current reimbursement rates along with
claim billing rules for related and unrelated donor expense. We will
specifically review what transplant centers need to “self-audit” in terms of
correctly prepared claims, including the reporting of all charges, professional
services, and submission of cost reporting information for donor search and
cell acquisition. At the end of the webinar, Susan Leppke, Director of
Public and Payer Policy at NMDP, will review key Medicare coverage changes
and provide an update on strategies for expanding Medicare coverage and
improving reimbursement. Come prepared with questions to ask during the
Q&A session at the end!
Register now for this free webinar.
Where can you find us next?
You can find the NMDP
Public and Payer Policy team exhibiting at these conferences:
Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health
Care Team, April 16-17 in
2018 CMSA Annual
Conference & Expo, June 19-23 in
If you are attending,
come say hello! We would love to chat with you.
Forward to a Friend
Please forward this email to others who would benefit from this information. If this email was forwarded to you, we invite you to subscribe.
If you have any questions or need additional information, please contact the Payer Policy team at PayerPolicy@nmdp.org. All of our resources are available on our website: Network.BeTheMatchClinical.org/Reimbursement.